To define the effects of withdrawing disease-modifying antirheumatic drug (DMARD) treatment from patients with established rheumatoid arthritis (RA) receiving stable, effective long-term DMARD treatment. A systematic literature search was conducted. Studies were included that were of high quality and ...
参考文献: [1] Koray Tascilar, Melanie Hagen,Arnd Kleyer,et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission(RETRO): a multicentre, randomised,controlled,open-label,phase 3 tria...
A new, Taiwanese study has confirmed these results, and shown that serum levels of rheumatoid factor (RF) and anti-cyclic-citrullinated peptide (anti-CCP) antibodies show a marked, progressive fall in patients with established RA given 3 months of treatment with etanercept plus DMARDs....
DMARDs for rheumatoid arthritis linked to lower dementia risk A study evaluating the link between rheumatoid arthritis treatment and dementia risk linked the use of DMARDs to lower dementia rates. Research published inRheumatic & Musculoskeletal Diseasefound that patients with rheumatoid...
Several biologic disease-modifying antirheumatic drugs (DMARDs) are currently approved for the treatment of rheumatoid arthritis (RA). There are 5 agents that either can be self-injected or could be self-injected with appropriate instruction. Of these, 4 are antibodies directed specifically toward tu...
来源:Holten K, Paulshus Sundlisater N, Lillegraven S, et al. Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment. Ann Rheum Dis. 2022 Mar;81(3...
RA(rheumatoid arthritis):类风湿关节炎;CAR-T(chimeric antigen receptor T cells):嵌合抗原受体T细胞 1.1 细胞因子阻断剂 肿瘤坏死因子抑制剂(TNFi)是最早应用于RA治疗的bDMARDs,其疗效充分,种类丰富。根据作用机制分为可溶性TNF受体-免疫球蛋白Fc段(IgG1 Fc)融合蛋白(代表药物依那西普,为上市最早的一种TNFi)和...
(EULAR) criteria.Methods:All patients had symptom duration from first swollen joint<2 years and wereDMARD nai ̈vewith an indication for DMARD treatment. Patients were stratified asseropositive ( positive rheumatoid factor (RF)+ and/or anticitrullinatedpeptide antibody (ACPA)+) or seronegative (...
Nakayama Y, Watanabe R, Yamamoto W, et al. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study. Rheumatology (Oxford). 2024 Feb 1;63(2):349-357. do...
D2T RA: difficult-to-treat rheumatoid arthritis; DMARDs, disease-modifying antirheumatic drugs. 4. Immune cells associated with inappropriate treatment response 4.1. T Cell It is well-established that T cells are involved in the development and chronicity of RA [107]. It has been found that ...